Abstract: A triazine compound, an intermediate thereof, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a triazine derivative as represented by formula (I?) or a pharmaceutically acceptable salt thereof. On the basis of retaining the effectiveness against SARS-CoV-2, the compound significantly prolongs the half-life period, reduces the dosage requirement, reduces side effects, expands the range of therapeutic window, and has very good prospects when used for manufacturing a drug for treating diseases related to coronavirus infections.

Abstract: Described herein is a dichloroacetic acid conjugating diphenyl ethane compound, and a preparation method and an application thereof. The dichloroacetic acid conjugating diphenyl ethane compound has a stable structure, low toxicity, a simple preparation process and a high yield, without necessity to preserve it in a dark place, and has anti-tumor activity against a variety of tumor cells cultured in vitro, and the anti-tumor effect in vivo.

Abstract: Chlorella mannogalactan (CM) or a sulfated Chlorella mannogalactan (SCM) compound and application of the SCM compound are disclosed. The CM is obtained by extracting total polysaccharides from Chlorella dry powder before performing separation and purification. The SCM compound is obtained by sulfation modification of the CM. The CM and the SCM compound both consist of mannose, 3-O-methyl-mannose, and galactose. The SCM compound and an excipient thereof form a pharmaceutical composition that can be used as a lyophilized powder injection or an aqueous solution for injection for prevention and/or treatment of thrombotic cardiovascular diseases. The CM or the SCM compound and the application of the SCM compound are adopted. The SCM has good water solubility and strong anticoagulant activity, which can be comparable to enoxaparin sodium.

Abstract: Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, bis-, tri-, tetra- or penta-substituted on a phenyl group; a linking group L1 is an alkyl or alkenyl group having 1, 2, 3, or 4 carbon atoms, a linking group L2 is oxygen, or an alkyl or alkoxy group having 1, 2, 3, or 4 carbon atoms, or an amino acid, or an alkyl group having 1, 2, 3, or 4 carbon atoms containing an amino moiety, or a furyl group, and an X group is O or —NH—. Further disclosed is a method for preparing such a derivative and a use of the same in the treatment of cancer, tumor diseases, and diseases caused by abnormal neovascularization in a human or non-human mammal, and a medicament or a composition containing the 5-fluorouracil derivative.

Abstract: Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, bis-, tri-, tetra- or penta-substituted on a phenyl group; a linking group L1 is an alkyl or alkenyl group having 1, 2, 3, or 4 carbon atoms, a linking group L2 is oxygen, or an alkyl or alkoxy group having 1, 2, 3, or 4 carbon atoms, or an amino acid, or an alkyl group having 1, 2, 3, or 4 carbon atoms containing an amino moiety, or a furyl group, and an X group is O or —NH—. Further disclosed is a method for preparing such a derivative and a use of the same in the treatment of cancer, tumor diseases, and diseases caused by abnormal neovascularization in a human or non-human mammal, and a medicament or a composition containing the 5-fluorouracil derivative.

Abstract: The invention discloses CA-4 antitumour drug, their synthetic methods and applications. The CA-4 antitumour drug are obtained by introducing an alkoxy group or a fluorine-containing alkoxy group at the 4? position of the natural product Combretastatin and modified with a functional chemical group at its 3? position. The CA-4 derivated anti-tumor drugs of the invention have inhibitory ability on two targets related to tubulin and arylsulfatase, and can be used for anti-tumor treatment.

Abstract: The present invention relates to compounds which act as modulators of the chloride channel CLC-7, assays for the identification of such compounds and methods of preventing, diagnosing, and treating osteoporosis and related disease states using such compounds.